What question did this study set out to answer?

To investigate how the PNPLA3 148M variant influences inflammation and necroptosis in macrophages related to MASLD.

January 24, 20260 citations

A PNPLA3-NACC1-RIPK3 pathway mediates macrophage necroptosis and inflammation in MASLD.

Key Points

To investigate how the PNPLA3 148M variant influences inflammation and necroptosis in macrophages related to MASLD.
Analyzed the macrophage-specific NF-κB-NACC1-RIPK3 signaling pathway
Assessed the role of the PNPLA3 variant in enhancing necroptosis
Evaluated hepatocyte steatosis and HSC activation in the context of inflammation
The PNPLA3 148M variant leads to increased necroptosis in macrophages
Enhanced inflammatory signaling significantly exacerbates hepatocyte steatosis
NACC1 is identified as a potential therapeutic target for individuals with the PNPLA3 variant.

Abstract

The PNPLA3 148M variant promotes MASLD through a macrophage-specific NF-κB-NACC1-RIPK3 axis that enhances necroptosis and inflammatory signaling, thereby exacerbating hepatocyte steatosis and HSC activation. NACC1 emerges as a tractable therapeutic target for genetically at-risk individuals.

Ask AI

Helpful

Bookmark

View Full Paper

Cite This Study

Wang et al. (2026) studied this question.

synapsesocial.com/papers/69746126bb9d90c67120b03f https://doi.org/10.1097/hc9.0000000000000890

Ask AI

Helpful

Bookmark

View Full Paper

January 24, 20260 citations

A PNPLA3-NACC1-RIPK3 pathway mediates macrophage necroptosis and inflammation in MASLD.

View Full Paper

XWXinjia Wang LBLu Bian ZFZhuoying Feng

Key Points

To investigate how the PNPLA3 148M variant influences inflammation and necroptosis in macrophages related to MASLD.
Analyzed the macrophage-specific NF-κB-NACC1-RIPK3 signaling pathway
Assessed the role of the PNPLA3 variant in enhancing necroptosis
Evaluated hepatocyte steatosis and HSC activation in the context of inflammation
The PNPLA3 148M variant leads to increased necroptosis in macrophages
Enhanced inflammatory signaling significantly exacerbates hepatocyte steatosis
NACC1 is identified as a potential therapeutic target for individuals with the PNPLA3 variant.

Abstract

Ask AI

Helpful

Bookmark

View Full Paper

Cite This Study

Wang et al. (2026) studied this question.

synapsesocial.com/papers/69746126bb9d90c67120b03f https://doi.org/10.1097/hc9.0000000000000890

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

Ask AI

Helpful

Bookmark

View Full Paper